Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 30306271.
- Also identified by DOI 10.1007/s00701-018-3697-3.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor-namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA-and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Brain Neoplasms
- Glioblastoma
- Neoplasm Recurrence, Local